Kidney Neoplasm Clinical Trial
Official title:
Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study
Positron emission tomography (PET) is a non-invasive imaging tool for monitoring functional and metabolic responses of biological events with specific radiotracer in vivo. The PET tracer [18F]Fluciclatide is an 18F radiolabeled small peptide containing the RGD (arginine-glycine-aspartate) tri-peptide, which preferentially binds with high affinity to αvβ3 and αvβ5 integrins. αvβ3-integrins are expressed at low levels on epithelial cells and mature endothelial cells but are expressed at high levels on activated endothelial cells in the neo-vasculature of a range of tumors and it also may regulate angiogenesis. If pazopanib acts mainly on active angiogenetic tumors, the quantitative uptake of [18F]Fluciclatide can be used to predict the effect of this antiangiogenic drug. The investigators expected the baseline tumor uptake in [18F]Fluciclatide to be able to predict treatment response, and planned a study of [18F]FluciclatidePET for patients with metastatic RCC who received pazopanib systemic therapy.
Subjects will receive treatment with pazopanib at a dose of 800 mg orally once daily. [18F]Fluciclatide imagings will be taken 2 times; 1) before systemic therapy (at baseline), 2) at one week after starting of Pazopanib. However, If the target lesion on the baseline PET cannot be discriminated compared to the background activity, the 2nd PET will not be done. Response evaluation by CT will be performed at baseline, at 6 week, at 12 week and every 8 weeks thereafter until the end of treatment. RECIST1.1 criteria for response will be applied. Patient will be treated with Pazopanib until there is disease progression, unacceptable toxicity or withdrawal of patient consent. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001302 -
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
|
Phase 1 | |
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Enrolling by invitation |
NCT02287987 -
CLamp vs Off Clamp Kidney During Partial Nephrectomy
|
N/A | |
Recruiting |
NCT04644432 -
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05817604 -
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
|
||
Completed |
NCT00888641 -
A Pilot Study of Renal Hypothermia During Partial Nephrectomy
|
Phase 1 | |
Completed |
NCT00199875 -
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
|
Phase 1 | |
Recruiting |
NCT00994188 -
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
|
N/A | |
Recruiting |
NCT02346435 -
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
|
||
Completed |
NCT01087060 -
Detection of Renal Malignancy of Complicated Renal Cysts
|
N/A | |
Recruiting |
NCT04258462 -
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
|
Phase 2 | |
Recruiting |
NCT00898365 -
Study of Kidney Tumors in Younger Patients
|
||
Recruiting |
NCT03996850 -
SPECT/CT for the Characterization of Renal Masses
|
||
Recruiting |
NCT04823923 -
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
|
N/A | |
Not yet recruiting |
NCT04681690 -
German National Registry for NSS
|
||
Not yet recruiting |
NCT05135832 -
Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma
|
N/A | |
Recruiting |
NCT04602702 -
Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors
|
||
Terminated |
NCT00005655 -
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05887245 -
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
|
||
Recruiting |
NCT06467097 -
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
|
Phase 3 |